Summit Creek Advisors LLC Sells 5,907 Shares of LeMaitre Vascular, Inc. $LMAT

Summit Creek Advisors LLC lessened its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 149,996 shares of the medical instruments supplier’s stock after selling 5,907 shares during the period. LeMaitre Vascular makes up about 1.9% of Summit Creek Advisors LLC’s holdings, making the stock its 25th biggest holding. Summit Creek Advisors LLC owned 0.66% of LeMaitre Vascular worth $12,165,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cornerstone Planning Group LLC grew its stake in LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 283 shares in the last quarter. MAI Capital Management purchased a new position in LeMaitre Vascular in the 3rd quarter worth approximately $38,000. Geneos Wealth Management Inc. grew its stake in LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares in the last quarter. EverSource Wealth Advisors LLC purchased a new position in LeMaitre Vascular in the 2nd quarter worth approximately $47,000. Finally, GAMMA Investing LLC grew its stake in LeMaitre Vascular by 32.7% in the 4th quarter. GAMMA Investing LLC now owns 727 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 179 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LeMaitre Vascular stock opened at $101.43 on Thursday. LeMaitre Vascular, Inc. has a 52-week low of $78.35 and a 52-week high of $118.01. The stock has a market capitalization of $2.32 billion, a price-to-earnings ratio of 37.43, a price-to-earnings-growth ratio of 2.81 and a beta of 0.60. The company has a fifty day moving average of $108.94 and a 200-day moving average of $95.20. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.02. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The company had revenue of $66.55 million during the quarter, compared to analysts’ expectations of $66.67 million. During the same quarter in the prior year, the company earned $0.48 EPS. The firm’s revenue was up 11.1% on a year-over-year basis. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities research analysts expect that LeMaitre Vascular, Inc. will post 3 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Investors of record on Thursday, May 21st will be issued a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a yield of 1.0%. The ex-dividend date is Thursday, May 21st. LeMaitre Vascular’s dividend payout ratio is currently 36.90%.

Insider Activity

In related news, insider Trent G. Kamke sold 2,928 shares of the company’s stock in a transaction on Friday, May 8th. The shares were sold at an average price of $107.00, for a total transaction of $313,296.00. Following the completion of the sale, the insider directly owned 3,749 shares in the company, valued at $401,143. This represents a 43.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction on Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the sale, the director owned 3,942 shares of the company’s stock, valued at $437,956.20. This represents a 56.13% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 269,891 shares of company stock valued at $28,969,086. 7.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wells Fargo & Company boosted their price target on shares of LeMaitre Vascular from $94.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Wednesday, May 6th. Citizens Jmp upped their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 6th. Wall Street Zen raised shares of LeMaitre Vascular from a “hold” rating to a “buy” rating in a research note on Saturday, February 21st. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Wednesday, May 6th. Finally, Barrington Research upped their price objective on shares of LeMaitre Vascular from $105.00 to $120.00 and gave the company an “outperform” rating in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $112.60.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.